Literature DB >> 22293798

Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion.

Turan Erdogan1, Yüksel Ciçek, Sinan Altan Kocaman, Aytun Canga, Mustafa Cetin, Emre Durakoglugil, Omer Satiroglu, Ahmet Temiz, Elif Ergül, Ismail Sahin, Mehmet Bostan.   

Abstract

OBJECTIVE: Bilirubin is a bile pigment with potent anti-oxidant properties; in previous studies it has been reported to be negatively associated with coronary artery disease (CAD). Although elevated serum bilirubin concentrations may protect against endothelial dysfunction, it is not clear whether higher serum bilirubin levels (SBLs) in physiological ranges may work in favor of good collateral development in patients with chronic total coronary occlusion (CTO).
METHODS: The study population consisted of patients who underwent coronary angiography with a suspicion of CAD. Patients who had CTO in at least one major coronary artery were included. Coronary angiograms of 179 eligible patients from our database were reanalyzed and 110 of them had good collateral development and 69 had poor collateral development according to the Cohen-Rentrop method.
RESULTS: Patients with good collateral development had a lower fasting plasma glucose level (FPG) (p=0.024) and higher SBLs in comparison to patients with poor collateral development (p<0.001). The number of CTO vessels (p=0.013) and left ventricular ejection fraction (EF%) were higher in good collateral group than poor collateral group (p=0.017). In multivariate analysis, FPG negatively (odds ratio [OR]: 0.981, p=0.003) and SBL (OR for per 0.1-mg/dL increase: 1.832, p<0.001) and the number of CTO vessels (OR: 5.642, p=0.007) were positively related to coronary collateral development.
CONCLUSION: This study suggests that higher bilirubin levels within relatively normal ranges were related with favorable coronary collateral growth in patients with CTO. SBL may be responsible for the difference in coronary collateral vessel development among different patients with coronary artery disease. The anti-inflammatory and anti-oxidant properties of bilirubin may mediate this effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293798     DOI: 10.2169/internalmedicine.51.6417

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Usefulness of serum bilirubin levels as a biomarker for long-term clinical outcomes after percutaneous coronary intervention.

Authors:  Hyun-Wook Kim; Dong-Hyun Choi; Leejin Lim; Young-Min Lee; Joon Tae Kang; Seung Seok Chae; Young-Jae Ki; Heesang Song; Young-Youp Koh
Journal:  Heart Vessels       Date:  2014-07-22       Impact factor: 2.037

2.  A novel predictor of infarct-related artery patency before percutaneous intervention and in-hospital outcomes for ST-segment elevation myocardial infarction patients: serum bilirubin level.

Authors:  Halit Acet; Faruk Ertş; Mehmet Ata Akıl; Nihat Polat; Mesut Aydın; Abdurrahman Akyüz; Hilal Ayçiçek; Sait Alan
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-06-26       Impact factor: 1.426

3.  Association of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fraction.

Authors:  Huan Zheng; Ye Li; Nanzi Xie
Journal:  Biol Res       Date:  2014-03-26       Impact factor: 5.612

Review 4.  Bilirubin in coronary artery disease: Cytotoxic or protective?

Authors:  Nancy Gupta; Tavankit Singh; Rahul Chaudhary; Sushil K Garg; Gurprataap Singh Sandhu; Varun Mittal; Rahul Gupta; Roxana Bodin; Sachin Sule
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

5.  Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

Authors:  Chengchun Tang; Hao Qian; Dong Wang; Yong Qiao; Gaoliang Yan
Journal:  Biomed Res Int       Date:  2019-05-28       Impact factor: 3.411

6.  Glucose or Altered Ceramide Biosynthesis Mediate Oxygen Deprivation Sensitivity Through Novel Pathways Revealed by Transcriptome Analysis in Caenorhabditis elegans.

Authors:  Mary L Ladage; Skylar D King; David J Burks; Daniel L Quan; Anastacia M Garcia; Rajeev K Azad; Pamela A Padilla
Journal:  G3 (Bethesda)       Date:  2016-10-13       Impact factor: 3.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.